What is the 13F Pro Quality Score for PRVA?

13F Pro ranks Privia Health Group, Inc. (PRVA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PRVA's current score at https://13fpro.ai/research/PRVA (free sign-up required for the full ranking).

Which hedge funds own the most PRVA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PRVA include BlackRock,, FMR, Durable Capital Partners. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/PRVA as soon as new 13F filings post.

Where does 13F Pro source PRVA data?

All Privia Health Group, Inc. fundamentals and ownership data come directly from SEC EDGAR. Privia Health Group, Inc. files with the SEC under CIK 1759655. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PRVA in?

Privia Health Group, Inc. (PRVA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PRVA research updated on 13F Pro?

PRVA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Privia Health Group, Inc.(PRVA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1759655 PRVA stock profile & AI dashboard →

13F Pro Quality Score

49.4/100

Rank #1,512 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

76.0/100

Profitability

39.6/100

Balance Sheet

46.0/100

Earnings Quality

22.5/100

Free Cash Flow

32.1/100

Institutional Flow

44.0/100

Revenue Scale

64.1/100

Dilution Risk

31.8/100

PRVA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Privia Health Group, Inc. (PRVA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PRVA at 49.4/100 on a 32-signal composite quality model, placing it at rank #1,512 of 2,879 stocks — the bottom half of the AI-ranked universe. PRVA scores in the top quartile across revenue growth (76.0). Areas of concern include earnings quality (22.5) and free cash flow (32.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 31.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Privia Health Group, Inc. reports quarterly revenue of $603.8M, net income of $3.1M, an operating margin of 1.2%. Top institutional holders of PRVA by reported 13-F value include BlackRock,, FMR, Durable Capital Partners, based on the most recent SEC filings. PRVA trades on the Nasdaq exchange and files with the SEC under CIK 1759655. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PRVA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Privia Health Group, Inc. directly from SEC EDGAR. Privia Health Group, Inc.'s 13F Pro composite quality score has ranged between 8 and 76 since 2026, currently 49.4 — an improving long-term trajectory across 36 quarterly and live scoring snapshots.

Revenue

Q1 2026

$603.8M

Net Income

Q1 2026

$3.1M

Free Cash Flow

Q1 2026

$-49.5M

Operating Margin

Q1 2026

1.2%

ROIC

Q1 2026

1.0%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+4.7% YoY

$1.74BFY 2024

FY19 $786.4MFY20 $817.1MFY23 $1.66BFY24 $1.74B

Net Income

-37.7% YoY

$14.4MFY 2024

FY19 $8.2MFY20 $31.2MFY23 $23.1MFY24 $14.4M

Operating Income

-17.8% YoY

$17.0MFY 2024

FY19 $16.1MFY20 $25.4MFY23 $20.6MFY24 $17.0M

EPS (Diluted)

-42.1% YoY

$0.11FY 2024

FY19 $0.09FY20 $0.33FY23 $0.19FY24 $0.11

Total Assets

+13.6% YoY

$1.14BFY 2024

FY19 —FY20 $329.0MFY23 $999.9MFY24 $1.14B

Op. Cash Flow

+35.3% YoY

$109.3MFY 2024

FY19 $24.4MFY20 $38.9MFY23 $80.8MFY24 $109.3M

Metric	FY 2024	FY 2023	FY 2020	FY 2019	FY 2018
Revenue	$1.74B +4.7%	$1.66B +102.9%	$817.1M +3.9%	$786.4M	—
Net Income	$14.4M -37.7%	$23.1M -26.1%	$31.2M +279.0%	$8.2M	—
Operating Income	$17.0M -17.8%	$20.6M -18.6%	$25.4M +58.0%	$16.1M	—
EPS (Diluted)	$0.11 -42.1%	$0.19 -42.4%	$0.33 +266.7%	$0.09	—
Total Assets	$1.14B +13.6%	$999.9M +203.9%	$329.0M	—	—
Operating Cash Flow	$109.3M +35.3%	$80.8M +107.7%	$38.9M +59.7%	$24.4M	—

AI Insight: PRVA Financial Trends

Revenue growth accelerated to 26% year-over-year in Q1 2026, but operating cash flow turned negative for the second consecutive Q1.

• Revenue grew from $422M in Q2 2024 to $604M in Q1 2026, representing 43% growth over seven quarters.

• Net income doubled from $3M in Q2 2025 to $7M in Q3 2025 before moderating to $3M in Q1 2026.

• Operating income peaked at $14M in Q3 2025 but declined to $7M in Q1 2026.

• Equity steadily increased from $595M in Q2 2024 to $753M in Q1 2026.

⚠ Operating cash flow turned negative in both Q1 2025 (-$24M) and Q1 2026 (-$49M), showing worsening seasonal pattern.

⚠ Q4 2025 revenue of $541M declined from Q3 2025's $580M, breaking the sequential growth trend.

AI Insight: PRVA Ratio Trends

PRVA's profitability shows high volatility with operating margin swinging from 2.5% in Q3 2025 to 1.2% in Q1 2026.

• Operating margin peaked at 2.5% in Q3 2025 before declining to 1.2% in Q1 2026.

• ROIC hit 8.1% in Q3 2025 but dropped to 3.9% in Q1 2026, showing significant quarterly volatility.

• Net profit margin compressed from 1.7% in Q4 2025 to 0.5% in Q1 2026.

⚠ Quarterly margin swings suggest unstable operational performance or seasonal headwinds requiring monitoring.

⚠ Q2 2025 showed particularly weak metrics across all profitability measures before subsequent recovery.

Get alerted when PRVA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Privia Health Group, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PRVA

BlackRock, Inc.
$392.0M19,057,910 sh
FMR LLC
$268.3M13,045,542 sh
Durable Capital Partners LP
$248.6M12,087,843 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$129.2M6,281,542 sh
Rubicon Founders LLC
$122.4M5,948,664 sh
VANGUARD CAPITAL MANAGEMENT LLC
$103.0M5,008,823 sh
STATE STREET CORP
$92.4M4,489,900 sh
RIVERBRIDGE PARTNERS LLC
$80.6M3,917,948 sh
Bank of New York Mellon Corp
$60.5M2,943,493 sh
GEODE CAPITAL MANAGEMENT, LLC
$59.6M2,895,534 sh

Fund	Value	Shares
BlackRock, Inc.	$392.0M	19,057,910
FMR LLC	$268.3M	13,045,542
Durable Capital Partners LP	$248.6M	12,087,843
VANGUARD PORTFOLIO MANAGEMENT LLC	$129.2M	6,281,542
Rubicon Founders LLC	$122.4M	5,948,664
VANGUARD CAPITAL MANAGEMENT LLC	$103.0M	5,008,823
STATE STREET CORP	$92.4M	4,489,900
RIVERBRIDGE PARTNERS LLC	$80.6M	3,917,948
Bank of New York Mellon Corp	$60.5M	2,943,493
GEODE CAPITAL MANAGEMENT, LLC	$59.6M	2,895,534

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PRVA on your watchlist

Track score changes the day Privia Health Group, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PRVA a good stock to buy?

13F Pro's AI-powered analysis of Privia Health Group, Inc. (PRVA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PRVA are available on the PRVA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PRVA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PRVA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Privia Health Group, Inc.'s investment landscape.